Clinical Trials Logo

Clinical Trial Summary

Use of the drug interferon-alpha (IFN-A), is associated with frequent and well characterized side effects like neurotoxicity. Neurotoxicity can cause symptoms of depression, agitation, anxiety, and/or confusion.

The NIDDK is conducting a research study called, "Combination of Alpha Interferon with Long Term Ribavirin Therapy for Patients with Chronic Hepatitis C" (98-DK-0003). Patients participating in it are receiving interferon-alpha in addition to an antiviral medication called ribavirin. Researchers at the NIMH intend to study patients to learn more about how different medications can influence mood, thoughts and behavior.

The primary purpose of this study is to determine if treatment with IFN-A in combination with ribavirin alters human brain biochemistry as measured by proton magnetic resonance spectroscopy (MRS).

MRS uses strong magnetic fields in order to measure biochemical products of metabolism found in the brain. Researchers intend to perform MRS scans before, during, and after patients receive their medications

Researchers believe that the combination of IFN-A/Ribavirin will directly affect specific areas of the brain and as a result, some patients will develop specific mood or cognitive symptoms. Patients often must stop taking these medications because of the side effects.

This study will not contribute directly to the treatment of patient's Hepatitis C condition. However, the information gathered from this study will help researchers better understand the neuropsychiatric affects associated with interferon alpha and ribavirin therapy.


Clinical Trial Description

The systemic administration of interferon-alpha (IFN-A) is associated with frequent and well characterized neuropsychiatric toxicity. The primary purpose of this study is to determine if treatment with IFN-A in combination with ribavirin alters human brain biochemistry as measured by proton magnetic resonance spectroscopy. The study population will be drawn from subjects simultaneously enrolled in a NIDDK protocol (98-DK-0003) that employs IFN-A and ribavirin for the treatment of hepatitis C virus (HCV) infection. Subjects will be evaluated prior to IFN-A/ribavirin treatment and then followed prospectively with the specific aim of identifying the emergence of central nervous system (CNS) effects. The principal outcome measures will be as follows: determinations of specific brain metabolites as measured by proton magnetic resonance spectroscopy (1H-MRS), a brief, non-invasive, and minimal risk procedure; ratings of mood, cognitive, and behavioral symptoms.

The hypotheses being tested in this study are as follows:

1. Treatment with IFN-A/ribavirin will decrease measures of neuronal integrity (NAA/CRE ratio) in a brain region specific fashion.

2. The degree of change in NAA/CRE in certain brain regions (e.g. prefrontal cortex) will correspond to the development of mood or cognitive symptoms.

The questions being asked in this study are relevant to the clinical management of HCV patients, since adverse neuropsychiatric effects of IFN-A and ribavirin frequently complicate protocol participation and occasionally result in a subject being taken off protocol. There are no anticipated number of patient days per year required for this study, as all participants will be simultaneously enrolled in NIDDK protocol 98-DK-0003. ;


Study Design

N/A


Related Conditions & MeSH terms


NCT number NCT00001547
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase N/A
Start date June 1996
Completion date June 2002

See also
  Status Clinical Trial Phase
Recruiting NCT06102850 - Adaptation of Critical Time Intervention for Young Adults With MH Challenges N/A
Completed NCT05649449 - Testing Self-Directed Care in Florida N/A
Not yet recruiting NCT05886595 - Being Young : My Mental Health
Recruiting NCT04157062 - An Open-Label Trial of Repetitive Transcranial Magnetic Stimulation for Opioid Use Disorder N/A
Completed NCT04505540 - Start Treatment and Recovery for Opioid Use Disorder N/A
Withdrawn NCT03236766 - Engaging Pacific Islander Perspectives on Mental Illness and Mental Health Services N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Not yet recruiting NCT04071145 - Using Sensors to Measure Drug Concentrations in Exhaled Breath
Completed NCT01922258 - Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Phase 3
Completed NCT04457635 - Effect of a 'Rapid-Return-to-work Program' in Mild Mental Disorders. N/A
Recruiting NCT06054061 - Evaluation the Efficacy "Think and Cope Positively" Program N/A
Completed NCT03118388 - Engaging Homeless Youth in Vocational Training to Meet Their Mental Health Needs Phase 2
Active, not recruiting NCT04196881 - Effect of Attention Deficit Hyperactivity Disorder Knowledge Improvement Program on Male Primary School Teachers N/A
Terminated NCT04028609 - Community Health Worker Intervention to Improve Post-Hospital Outcomes N/A
Active, not recruiting NCT03641664 - FCT Study: Reducing the Need for Out-of-Home Placements N/A
Completed NCT05019937 - Exploring Effectiveness and Mechanism of Change of an Implementation Strategy on Guideline Implementation in Schools N/A
Completed NCT03611998 - Survivors of Sex Trafficking: Occupation-Based Interventions for Executive Functioning N/A
Active, not recruiting NCT04148508 - App-based Mental Health Promotion in Young European Adults N/A
Completed NCT03704805 - Effect of a Psychological Intervention on Antiretroviral Therapy and Mental Health Outcomes in HIV-positive Adults in Zimbabwe N/A
Recruiting NCT05087446 - Effect of Early Assessment Team for Patients Referred to Outpatient Mental Health Care N/A